{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:46:54Z","timestamp":1768009614665,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.3816\/cbc.2010.n.004","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T23:51:52Z","timestamp":1265327512000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results"],"prefix":"10.3816","volume":"10","author":[{"given":"Patrick G.","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex F.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya","family":"Divgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravinder K.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2010.n.004_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","article-title":"Pamidronate in prevention of bone complications in MBC: a cost-effectiveness analysis","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib2","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in MBC","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.11139","article-title":"Effectiveness and cost of bisphosphonate therapy in tumor bone disease","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2010.n.004_bib5","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib6","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2010.n.004_bib7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2010.n.004_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.004_bib10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0959-8049(97)10155-1","article-title":"A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer","volume":"34","author":"Coleman","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.004_bib11","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.bone.2007.03.002","article-title":"Determinants of structure-function relationships among bisphosphonates","volume":"40","author":"Graham","year":"2007","journal-title":"Bone"},{"key":"10.3816\/CBC.2010.n.004_bib12","first-page":"1359","article-title":"Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning","volume":"42","author":"Carrasquillo","year":"2001","journal-title":"J Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/030089160509100115","article-title":"False negative bone scintigraphy in a patient with primary breast cancer: a possible transient phenomenon of bisphosphonate (alendronate) treatment","volume":"91","author":"Demirkan","year":"2005","journal-title":"Tumori"},{"key":"10.3816\/CBC.2010.n.004_bib14","first-page":"748","article-title":"Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy","volume":"33","author":"Hommeyer","year":"1992","journal-title":"J Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00003072-198804000-00008","article-title":"False-negative bone imaging due to etidronate disodium therapy","volume":"13","author":"Krasnow","year":"1988","journal-title":"Clin Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib16","first-page":"1039","article-title":"Effect of clodronate treatment on bone scintigraphy in MBC","volume":"34","author":"Pecherstorfer","year":"1993","journal-title":"J Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib17","first-page":"1589","article-title":"Bone scintigraphy following intravenous pamidronate for Paget's disease of bone","volume":"33","author":"Ryan","year":"1992","journal-title":"J Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib18","first-page":"1782","article-title":"Duration of etidronate effect demonstrated by serial bone scintigraphy","volume":"32","author":"Sandler","year":"1991","journal-title":"J Nucl Med"},{"key":"10.3816\/CBC.2010.n.004_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2010.n.004_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.004_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.3816\/CBC.2010.n.004_bib22","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.3816\/CBC.2010.n.004_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3816\/CBC.2010.n.004_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02555856","article-title":"The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases","volume":"49","author":"Daley-Yates","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.3816\/CBC.2010.n.004_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF03257396","article-title":"Renal and non-renal clearance of clodronate in malignancy and renal impairment","volume":"7","author":"O'Rourke","year":"1994","journal-title":"Drug Invest"},{"key":"10.3816\/CBC.2010.n.004_bib26","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2010.n.004_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CBC.2010.n.004_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2010.n.004_bib29","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1359\/JBMR.050522","article-title":"Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases","volume":"20","author":"Cremers","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2010.n.004_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1259\/dmfr\/27458726","article-title":"Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws","volume":"35","author":"Chiandussi","year":"2006","journal-title":"Dentomaxillofac Radiol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911700040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911700040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:08Z","timestamp":1761512768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911700040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1526820911700040"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2010.n.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2010.n.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}